Name of study:
Precision Interventions for Severe Asthma (PrecISE)
Targeted disease:
Asthma
Purpose of study:
PrecISE is a clinical study sponsored by the U.S. National Heart, Lung, and Blood Institute (NHLBI) to investigate several treatments for severe asthma. PrecISE will enroll 800 adults and teenagers (ages 12 years and older) with severe asthma who have symptoms that are not well-controlled on high dose of inhaled corticosteroids including those who have frequent asthma attacks. Each person who agrees to enroll in the PrecISE study will receive several treatments for research purposes based on their type of severe asthma.The goal of PrecISE is to understand how to treat different types of severe asthma, by using precision medicine. Precision medicine is an approach that targets treatments to defined subgroups of patients who share similar characteristics, for example, patients with a certain genetic variation or patients with high number of blood eosinophils. Researchers from over 30 locations across the US, as well as sites in Canada and the United Kingdom, are involved in PrecISE.
Is this a pre- or post- market study?:
Pre-Market Study
Is the study of a controlled or observational design?
Controlled
What is the funding source?:
NIH/NHLBI
Where is the study being conducted?
Multi-Center Trial
Lead Institution:
University of North Carolina Chapel Hill
City and State:
Nationwide
When the study is being conducted:
Start Date: Ongoing
End date: 6/1/2023
What website should a person use to register for the study?
https://preciseasthma.org/preciseweb/Study-Sites-By-Location
Who should a person contact to register for the study?
See names for each site at: https://preciseasthma.org/preciseweb/Study-Sites-By-Location
Who is sponsoring this study?
NIH/NHLBI
What is the identifier for this study on ClinicalTrials.gov?
NCT04129931
Page last updated: June 7, 2024